FDA Drug Recalls

Recalls / Class III

Class IIID-684-2013

Product

Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58

Brand name
Balziva
Generic name
Norethindrone And Ethinyl Estradiol
NDC
0555-9034
FDA application
ANDA076238
Affected lot / code info
NDC 0555-9034-58, Lot numbers 33802100A, exp 3/2013; 33802266A, exp 3/2013; and 33802832A, exp 8/2013.

Why it was recalled

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Recalling firm

Firm
Teva Pharmaceuticals USA, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
650 Cathill Rd, N/A, Sellersville, Pennsylvania 18960-1512

Distribution

Quantity
36,708 blister packs
Distribution pattern
Nationwide distribution. No foreign or government accounts.

Timeline

Recall initiated
2013-03-15
FDA classified
2013-07-05
Posted by FDA
2013-07-17
Terminated
2014-04-10
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-684-2013. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.